Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: A phase I/II study

BJU International

Volumn 94, Issue 3, 2004, Pages 412-418

  Pandha, Hardev S ^a   John, Robert J ^a   Hutchinson, James ^a   James, Nick ^c   Whelan, Mike ^b   Corbishley, Catherine ^b   Dalgleish, Angus G ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

Allogeneic; Cryopreservation; Dendritic cell; Keyhole limpet haemocyanin; Vaccine

Indexed keywords

CYTOKINE; GAMMA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; KEYHOLE LIMPET HEMOCYANIN; PROSTATE SPECIFIC ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CELL INFILTRATION; CELL LYSATE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DELAYED HYPERSENSITIVITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MALE; METASTASIS; MIXED LYMPHOCYTE REACTION; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SIDE EFFECT; SKIN BIOPSY; TH1 CELL; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; AGED; CANCER VACCINES; CARCINOMA, RENAL CELL; CRYOPRESERVATION; CYTOKINES; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; HEMOCYANIN; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; T-LYMPHOCYTES;

EID: 4344637057     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04922.x     Document Type: Article

References (19)

1. Newling D, Fossa SD, Andersson L et al. Assessment of hormone refractory prostate cancer. Urology 1997; 49 (Suppl. 4A): 46-53
2. Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4: 385-90
3. Ridgway D. The first 1000 dendritic cell vaccines. Cancer Invest 2003; 21: 873-86
4. John J, Hutchinson J, Dalgleish A, Pandha H. Cryopreservation of immature monocyte-derived dendritic cells results in enhanced cell maturation but reduced endocytic activity and efficiency of adenoviral transduction. J Immunol Meth 2002; 9239: 1-14
5. Eaton JD, Perry MJ, Nicholson S et al. Allogeneic whole-cell vaccine: a phase I/II study in men with hormone-refractory prostate cancer. BJU Int 2002; 89: 19-26
6. Fabre JW. The allogeneic response and tumor immunity. Nat Med 2001; 7: 649-52
7. Shimizu K, Thomas EK, Giedlin M, Mule JJ. Enhancement of tumor lysate- and peptide-pulsed dendritic cell-based vaccines by the addition of foreign helper protein. Cancer Res 2001; 61: 2618-24
8. Therasse P. Measuring the clinical response. What does it mean? Eur J Cancer 2002; 38: 1817-23
9. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998; 4: 328-32.20
10. Kiuchi T, Kato H, Kanaya S et al. Spontaneous proliferation of peripheral blood lymphocytes as an indicator of intragraft immune activation in liver transplant patients. Clin Transplant 1994; 8: 382-7
11. Flanigan RC, Salmon SE, Blumenstein BA et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001; 345: 1655-9
12. Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen. Prostate 1996; 29: 371-80
13. Heiser A, Coleman D, Dannull J et al. Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. J Clin Invest 2002; 109: 409-1722
14. Small EJ, Fratesi P, Reese DM et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 2000; 18: 3894-903
15. Burch PA, Breen JK, Buckner JC et al. Priming tissue-specific cellular immunity in a phase I trial of autologous dendritic cells for prostate cancer. Clin Cancer Res 2000; 6: 2175-82
16. Lodge PA, Jones LA, Bader RA, Murphy GP, Salgaller ML. Dendritic cell-based immunotherapy of prostate cancer: immune monitoring of a phase II clinical trial. Cancer Res 2000; 60: 829-33
17. Larsson M, Messmer D, Somersan S et al. Requirement of mature dendritic cells for efficient activation of influenza A-specific memory CD8+ T cells. J Immunol 2000; 165: 1182-90
18. Barratt-Boyes SM, Zimmer MI, Harshyne LA et al. 3rd et al. Maturation and trafficking of monocyte-derived dendritic cells in monkeys: implications for dendritic cell-based vaccines. J Immunol 2000; 164: 2487-95
19. Lambert LA, Gibson GR, Maloney M, Durell B, Noelle RJ, Barth RJ Jr. Intranodal immunization with tumor lysate-pulsed dendritic cells enhances protective antitumor immunity. Cancer Res 2001; 61: 641-6